Table 2 Immunophenotypic features of SC/LH versus non-SC/H ALK+ anaplastic large cell lymphoma.
Immunophenotype | SC/LH (n = 18) | non-SC/LH (n = 84) | P value |
|---|---|---|---|
CD2+ | 92% (11/12) | 36% (15/42) | 0.0007 |
CD3+ | 81% (13/16) | 15% (11/73) | 0.0001 |
CD4+ | 62% (8/13) | 69% (36/52) | 0.74 |
CD5+ | 36% (5/14) | 45% (26/58) | 0.38 |
CD7+ | 80% (8/10) | 37% (11/30) | 0.03 |
CD8+ | 54% (7/13) | 7% (3/43) | 0.0006 |
CD4+CD8+ | 31% (4/13) | 3% (1/40) | 0.0009 |
CD25+ | 57% (4/7) | 90% (9/10) | 0.25 |
CD43+ | 100% (6/6) | 76% (29/38) | 0.32 |
CD45+ | 91% (10/11) | 73% (38/52) | 0.27 |
CD56+ | 50% (3/6) | 23% (3/13) | 0.32 |
TCR A/B | 40% (2/5) | 71% (5/7) | 0.56 |
TCR G/D | 0% (0/5) | 0% (0/5) | 1 |
Granzyme B+ | 100% (8/8) | 91% (10/11) | 1 |
EMA+ | 83% (5/6) | 89% (31/35) | 0.57 |
